Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
No, anti-amyloid drugs don’t help everyone with Alzheimer’s—and understanding why is critical if you’re considering them for yourself or a loved one. These newer medications, including aducanumab (Aduhelm) and more recently lecanemab (Leqembi) and donanemab, do slow cognitive decline in early Alzheimer’s disease, but they work only for people in specific stages with particular genetic and biological profiles. They come with serious drawbacks, including a risk of amyloid-related imaging abnormalities (ARIA), which can cause brain swelling or microhemorrhages. If your family member is in late-stage dementia, these drugs won’t help.
Even in early stages, they’re not a cure—they might slow decline by a matter of months. The critical detail: anti-amyloid monoclonal antibodies target amyloid-beta, one of the proteins that accumulates in Alzheimer’s brains, but amyloid isn’t the whole story. Some people with amyloid buildup never develop symptoms, while some with Alzheimer’s symptoms don’t have high amyloid levels. This biological reality means these drugs are precision medicines, not blanket treatments. A person with mild cognitive impairment (MCI) caused by Alzheimer’s who carries the APOE4 gene and has documented amyloid in their brain might benefit from lecanemab—but the same medication is pointless and potentially harmful for someone with moderate dementia, or someone without amyloid pathology.
Table of Contents
- Who Actually Benefits From Anti-Amyloid Drugs?
- The Side Effects and Safety Concerns That Change the Equation
- What the Clinical Trial Data Actually Shows About Slowing Decline
- Cost, Access, and Practical Realities for Families
- The Amyloid Hypothesis Itself Isn’t Proven to Be the Whole Story
- Age and Comorbidity as Hidden Limiting Factors
- The Future: Combination Therapies and Ongoing Research
- Conclusion
- Frequently Asked Questions
Who Actually Benefits From Anti-Amyloid Drugs?
Anti-amyloid drugs only work in a narrow window: early symptomatic Alzheimer’s disease, before significant neurodegeneration has occurred. This means people with mild cognitive impairment (MCI) or mild dementia stage who have been confirmed to have amyloid pathology through biomarkers (amyloid PET scans, cerebrospinal fluid tests, or blood biomarkers like phosphorylated tau and phosphorylated amyloid-beta ratios). The clinical trials that showed benefit enrolled people at this specific stage, and the slowdown in cognitive decline—typically 25 to 35 percent—was measured in this population. Someone with moderate dementia, where significant brain damage has already accumulated, won’t see cognitive improvement because too many neurons have already been lost. Your genetic makeup matters enormously.
Carriers of the APOE4 gene are at higher risk for Alzheimer’s but also may respond differently to treatment. Meanwhile, people without amyloid pathology—confirmed by biomarkers—should not take these drugs at all, since the medication has no target to work on and only adds risk. This is why biomarker testing has become essential before starting anti-amyloid therapy. A patient might have memory complaints and mild cognitive decline, but if their amyloid levels are normal, the cognitive changes may be due to vascular issues, Lewy bodies (Parkinson’s-like pathology), tau tangles without amyloid, or simply normal aging. Starting an anti-amyloid drug on someone in this situation exposes them to side effects without any possibility of benefit.
The Side Effects and Safety Concerns That Change the Equation
Amyloid-related imaging abnormalities (ARIA) are the elephant in the room with these medications. ARIA-E is brain microedema (swelling), and ARIA-H is microhemorrhages (tiny bleeds). In lecanemab trials, ARIA-E occurred in about 21 percent of patients on the drug versus 9 percent on placebo; ARIA-H occurred in about 17 percent of the drug group versus 9 percent of placebo. Most of these are asymptomatic—caught on MRI scans but causing no noticeable symptoms—but some people develop confusion, headaches, vision changes, or balance problems from ARIA. There is no guaranteed way to predict who will develop ARIA before starting treatment.
The risk increases significantly for people taking blood thinners, those with cerebral amyloid angiopathy (CAA), and those with more advanced disease. Regular MRI monitoring is required, which adds cost (often $3,000 to $5,000 per scan without insurance) and inconvenience. For some patients, a single symptom-causing ARIA event is enough reason to stop the medication, meaning they’ve already incurred the risks and the medication gets discontinued. Additionally, these drugs must be infused regularly—lecanemab requires biweekly intravenous infusions—which demands reliable access to an infusion center, reliable veins, and the time commitment of multiple hours every two weeks. For someone with limited mobility, no transportation, or caregiving challenges, this practical burden alone may outweigh the modest cognitive benefit.
What the Clinical Trial Data Actually Shows About Slowing Decline
The most optimistic interpretation of lecanemab’s trial data (the Clarity trial, completed in 2022) showed about 27 percent slowing of cognitive decline over 18 months in people with MCI or mild dementia—a reduction from losing about 0.45 points on the ADAS-cog14 scale per year to losing about 0.35 points. In concrete terms, that means someone who would have declined over 18 months might instead decline about 30 percent less. It sounds meaningful until you translate it to real life: over 18 months, untreated patients averaged a 35-percent decline in cognitive function, while treated patients averaged about 25 percent. Both groups got worse. The treatment didn’t stop decline; it modestly slowed it.
Donanemab, approved more recently, showed similar or slightly better results in trials, with a 35 percent slowing of decline, but the long-term durability of this benefit beyond the trial period remains uncertain. Neither drug has shown evidence of working in moderate or advanced dementia. There are no head-to-head trials comparing anti-amyloid drugs to each other, so claims that one is definitively better than another are speculative. Most importantly, the trials didn’t compare anti-amyloid monoclonal antibodies to other interventions like cognitive behavioral therapy, physical activity, cognitive training, or optimized management of vascular risk factors—all of which have supporting evidence for cognitive benefit. Someone choosing lecanemab is often implicitly choosing not to pursue those other avenues with equal intensity, since time and resources are finite.
Cost, Access, and Practical Realities for Families
Lecanemab costs approximately $26,500 per year, while donanemab costs around $32,000 annually. Medicare now covers lecanemab for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease with confirmed amyloid pathology, but private insurance coverage varies, and many patients will face out-of-pocket costs or complex prior authorization processes. Even with Medicare coverage, patients pay 20 percent coinsurance, which can total thousands of dollars, plus the cost of required MRI monitoring, neurology visits for follow-up, and infusion administration fees if the drug is given at an infusion center rather than a hospital.
For families making this decision, the real-world tradeoff is worth spelling out: you’re paying significant money and time (biweekly infusions) for a treatment that will slow but not stop cognitive decline, that carries a real but usually asymptomatic risk of brain swelling or bleeding, and that must be monitored with regular brain imaging. You’re doing this in early disease stages when the person can still benefit from other interventions—exercise programs, social engagement, cognitive training, sleep optimization, management of hypertension and diabetes, hearing correction, and management of depression or anxiety. No anti-amyloid drug provides the emotional, social, or lifestyle support that can meaningfully affect quality of life in ways that imaging biomarkers never capture. For some families, that $26,500 might be better spent on a part-time care coordinator, a gym membership with personal training, or a cognitive rehabilitation program.
The Amyloid Hypothesis Itself Isn’t Proven to Be the Whole Story
The foundation of anti-amyloid therapy rests on the amyloid hypothesis: the idea that amyloid-beta accumulation is the primary driver of Alzheimer’s disease. While amyloid clearly plays a role, the hypothesis isn’t fully proven, and treatment success doesn’t mean the hypothesis is true. It’s possible that amyloid is a consequence of aging and tau pathology rather than a primary cause, or that Alzheimer’s is actually multiple diseases with different biological drivers. Some people with high amyloid levels never develop cognitive symptoms, suggesting amyloid alone isn’t sufficient to cause disease. Some people with Alzheimer’s dementia have relatively low amyloid but abundant tau tangles or other pathologies.
This means anti-amyloid treatment addresses only one piece of a complex puzzle. For some patients, targeting amyloid successfully slows decline because amyloid happens to be driving their disease. For others, their cognitive decline is driven primarily by tau pathology, vascular changes, Lewy body pathology, or neuroinflammation—domains where current anti-amyloid drugs have no effect. There are no reliable biomarkers that predict whether someone’s disease is amyloid-driven or driven by other pathologies, so clinicians and patients are essentially making an educated guess. This uncertainty should temper expectations and should be part of the informed consent discussion before starting treatment.
Age and Comorbidity as Hidden Limiting Factors
Anti-amyloid drugs have been studied primarily in people in their 60s and 70s, not in very old adults (85+) or in people with significant comorbidities like heart disease, stroke history, or kidney disease. If your loved one is very old or has complex medical problems, the evidence for benefit becomes even thinner, and the risk of side effects may increase.
Additionally, people taking anticoagulants for atrial fibrillation or other reasons have higher risks for ARIA-H (microhemorrhages), which creates a painful choice: should they stop the blood thinner (risking stroke) or stop the anti-amyloid drug (losing potential cognitive benefit)? Someone with untreated hypertension, which damages blood vessel walls and increases stroke and bleeding risks, should ideally have blood pressure optimized before starting an anti-amyloid drug—but many patients don’t have well-controlled hypertension when they present for cognitive decline evaluation. The practical reality is that anti-amyloid drugs work best in relatively healthy patients with good cardiovascular control and no significant comorbidities. For the frail, the elderly, and the medically complex, benefit is speculative and risks are real.
The Future: Combination Therapies and Ongoing Research
The research pipeline includes combination approaches that may eventually prove more effective than anti-amyloid monotherapy alone. Tau-targeted therapies are in development, as are anti-inflammatory agents and therapies targeting other pathological proteins. Some future protocols may combine anti-amyloid drugs with tau inhibitors, allowing treatment of two pathologies simultaneously. However, these combinations are not yet approved, and using multiple investigational therapies together in real practice introduces unknown risks.
The field is moving toward precision medicine approaches that match the specific pathology in a person’s brain to the specific drug most likely to target it—but we’re not there yet. The most honest statement about anti-amyloid drugs in 2026 is this: they offer a modest, measurable slowing of cognitive decline in a specific subgroup of people with early Alzheimer’s disease and confirmed amyloid pathology, but they are not disease-modifying cures, they don’t work for everyone, and they carry real risks. Future treatments will likely be more effective, more specific, and developed based on individual biomarker profiles. For now, anti-amyloid therapy is one option among many, appropriate for some people and not appropriate for others—and that determination requires careful assessment by a knowledgeable clinician, informed discussion with the patient and family, and realistic expectations.
Conclusion
The simple answer to whether anti-amyloid drugs help everyone with Alzheimer’s is no—but the practical answer for individual people is more nuanced. These medications can slow cognitive decline by about 25 to 35 percent in people with mild cognitive impairment or mild dementia who have documented amyloid pathology in their brains. That’s a measurable benefit, but not a cure, and it comes with real risks including brain swelling or microhemorrhages, the need for regular invasive brain imaging, ongoing intravenous infusions, and significant financial cost. The decision to start an anti-amyloid drug should depend on disease stage, confirmed biomarker status, age, comorbidities, access and resources, and honest conversation about what “slowing decline” actually means in a person’s life.
If you’re considering anti-amyloid therapy for yourself or a loved one, ask your neurologist or geriatrician whether you meet the specific criteria: mild cognitive impairment or mild dementia stage, confirmed amyloid pathology (not assumed, but proven by biomarker testing), no contraindications like uncontrolled bleeding risk or severe brain bleeding disease, and realistic expectations about what the treatment will and won’t do. Don’t assume that because a treatment exists, it’s right for your situation. The most effective Alzheimer’s interventions for most people remain the basics: exercise, cognitive engagement, social connection, sleep, management of cardiovascular risk factors, and hearing correction. Anti-amyloid drugs, where appropriate, are best used alongside those foundations, not as a replacement for them.
Frequently Asked Questions
Do anti-amyloid drugs cure Alzheimer’s?
No. They slow cognitive decline by about 25 to 35 percent in people with mild cognitive impairment or mild dementia due to Alzheimer’s disease, meaning decline happens more slowly but does not stop. There is no cure for Alzheimer’s disease at present.
Who should take anti-amyloid drugs?
People with mild cognitive impairment or mild dementia who have confirmed amyloid pathology (verified through biomarker testing), who are willing to commit to biweekly infusions, who can tolerate the risk of ARIA, and whose other medical conditions and medications allow safe use of the drug.
What is ARIA and how common is it?
Amyloid-related imaging abnormalities are brain swelling (ARIA-E) or tiny microhemorrhages (ARIA-H) that appear on MRI scans. They occur in roughly 20 to 30 percent of people taking lecanemab versus 10 percent on placebo. Most are asymptomatic, but some cause confusion, headache, or balance problems.
How much do anti-amyloid drugs cost?
Lecanemab costs approximately $26,500 per year, and donanemab costs around $32,000 annually. Medicare covers lecanemab with appropriate criteria, though patients pay 20 percent coinsurance. Private insurance coverage varies, and uninsured patients may face full out-of-pocket costs.
Can anti-amyloid drugs be used for people with moderate or advanced dementia?
No. These drugs have only been studied and shown benefit in people with mild cognitive impairment or mild dementia. They are not effective in later disease stages where significant neurodegeneration has already occurred.
What should I do instead of or alongside anti-amyloid drugs?
Evidence supports exercise (aerobic activity most consistently), cognitive engagement, social activity, optimized sleep, management of cardiovascular risk factors including blood pressure and diabetes, treatment of depression and anxiety, and correction of hearing loss if present. These interventions support cognitive health and should be pursued regardless of whether anti-amyloid therapy is chosen.
You Might Also Like
- Can Alzheimer’s Be Cured?
- Can Dementia Research Help Families Now?
- Can Dementia Care Be Improved With Better Staff Training?
For more, see NIH MedlinePlus — cognitive testing.
